On November 27, 2018 BioClin Therapeutics, Inc., a privately-held clinical stage drug development company focused on helping patients in the high unmet need of bladder cancer, reported the company is changing its name to Rainier Therapeutics, Inc (Press release, BioClin Therapeutics, NOV 27, 2018, View Source [SID1234531647]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new name, which will be implemented immediately, comes as the company prepares for late-stage, pivotal studies of its lead therapeutic candidate, vofatamab, which the company plans to initiate in 2019. Vofatamab (B-701) is an antibody specifically targeted against the FGFR3 receptor being developed for the treatment of patients in both early and late-stage bladder cancer.

"Our new logo incorporates the awe-inspiring image of a mountain and is designed to be symbolic for how we are striving to help our patients and caregivers, just as mountaineers strive to reach a summit. It also illustrates the challenging journey our patients face with this disease," commented Scott Myers, Chairman and CEO of Rainier Therapeutics. "We look forward to supporting late-stage clinical development efforts for vofatamab and are assembling an experienced, fully integrated team to provide support in multiple facets of operations."